NCT01601119View on ClinicalTrials.gov

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

CompletedOBSERVATIONAL
Enrollment

545

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Rebif

The subjects will receive Rebif as per the current practices or as directed by the physician.

OTHER

Other: Disease modifying therapies (DMT)

The subjects will receive other DMTs as per the current practices or as directed by the physician.

Trial Locations (1)

Unknown

Please contact the, Merck KGaA Communication Center For Locations

All Listed Sponsors
collaborator

Merck Serono Limited, UK

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01601119 - Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients | Biotech Hunter | Biotech Hunter